Keytruda pembrolizumab: Additional Phase Ib data

Data from 550 patients with advanced NSCLC in the open-label, U.S. Phase Ib KEYNOTE-001 trial showed that Keytruda led to a median OS of 22.1 months in treatment-naive patients (n=101) and 10.6 months in previously treated patients (n=449) at a median follow-up of 23.1 months. Keytruda also led to 18-month OS rates of 58.2% and 37% in treatment-naive and previously treated patients, respectively, and 24-month OS rates of 44.5% and 31.3%. In the treatment-naive cohort, Keytruda led to a median OS of 19.5 months in patients with 1-49% of PD-L1-positive tumor cells (n=52) and a median OS 14.7 months in patients with <1% of PD-L1-positive tumor cells (n=12). Median OS was not reached in treatment-naive patients with >=50% of PD-L1-positive tumor cells (n=27). In previously treated patients, Keytruda led to a median OS of 15.4 months in patients with >=50% of PD-L1-positive tumor cells (n=138), 8.2 months in patients with 1-49% of PD-L1-positive tumor cells (n=168) and 8.6 months in patients with <1% of PD-L1-positive tumor cells (n=90). ...